|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, it remains unclear, whether TPO mimetics influence the increase of blast cells and therefore to premature progression to AML.
|
28962071 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To address this limitation, we here transplanted primary human AML with isolated nucleophosmin (NPM1) mutation and AML with inv(16) in mice in which human versions of genes encoding cytokines important for myelopoiesis (macrophage colony-stimulating factor [M-CSF], interleukin-3, granulocyte-macrophage colony-stimulating factor, and thrombopoietin) were knocked into their respective mouse loci.
|
27581357 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The myeloproliferative leukemia virus oncogene, MPL, a homodimeric receptor activated by thrombopoietin (THPO), is mutated in myeloproliferative disorders but rarely in AML.
|
22613795 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These correlations between PLTs production (megakaryothrombopoiesis), TPO serum levels and TPO receptor (c-mpl) expression may help in the determination of risk-adapted AML patient groups and of targeted therapeutic strategies.
|
18357391 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Using this modeling approach to compare different sample groups within the AML samples, we identified a group of genes whose expression profiles correlated with that of thrombopoietin and found that genes whose expression associated with AML treatment outcome lie in recurrent chromosomal locations.
|
11435405 |
2001 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the effect of TPO on AML blasts, especially in CD7+ AML cases.
|
10721767 |
2000 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Here, we show that TPO, interleukin-3 (IL-3) and, at least in short-term assays, also interferon gamma (IFN gamma) induced proliferation in acute myeloid leukemia (AML-M7)-derived M-07e cells.
|
9766506 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, there is concern that MGDF might induce AML blast proliferation and thereby increase the risk of treatment failure.
|
9711904 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.
|
9196139 |
1997 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia.
|
9260579 |
1997 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
With regard to the French-American-British (FAB) classification, coexpression OF TPO and c-mpl was observed with high frequency in AML cases of M7-type.
|
8558944 |
1996 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Furthermore, rhTPO-induced proliferation of AML cells was augmented with the addition of interleukin-3 (IL-3), IL-6, stem cell factor, or granulocyte-macrophage colony-stimulating factor.
|
7541672 |
1995 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome.
|
8547088 |
1995 |